Education
About Us
Working with TipRanks
Follow Us
Seelos Therapeutics (SEELQ)
OTHER OTC:SEELQ
SEELQ Stock Chart & Stats
$0.18
$0.10(39.94%)
At close: 4:00 PM EST
$0.18
$0.10(39.94%)
Day’s Range― - ―
52-Week Range<$0.01 - $174.08
Previous CloseN/A
Volume6.71K
Average Volume (3M)8.69K
Market Cap
$1.00
Enterprise Value$11.36M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)<0.1
Beta25.00
Next Earnings
Apr 25, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)176.64
Shares Outstanding1,124,121
10 Day Avg. Volume2,464
30 Day Avg. Volume8,686
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap11.36M
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
SEELQ FAQ
What was Seelos Therapeutics’s price range in the past 12 months?
Seelos Therapeutics lowest stock price was <$0.01 and its highest was $174.08 in the past 12 months.
What is Seelos Therapeutics’s market cap?
Seelos Therapeutics’s market cap is $1.00.
When is Seelos Therapeutics’s upcoming earnings report date?
Seelos Therapeutics’s upcoming earnings report date is Apr 25, 2025 which is 244 days ago.
How were Seelos Therapeutics’s earnings last quarter?
Seelos Therapeutics released its earnings results on Aug 02, 2024. The company reported $0.124 earnings per share for the quarter, beating the consensus estimate of N/A by $0.124.
Is Seelos Therapeutics overvalued?
According to Wall Street analysts Seelos Therapeutics’s price is currently Overvalued.
Does Seelos Therapeutics pay dividends?
Seelos Therapeutics does not currently pay dividends.
What is Seelos Therapeutics’s EPS estimate?
Seelos Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Seelos Therapeutics have?
Seelos Therapeutics has 1,124,121 shares outstanding.
What happened to Seelos Therapeutics’s price movement after its last earnings report?
Seelos Therapeutics reported an EPS of $0.124 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -20%.
Which hedge fund is a major shareholder of Seelos Therapeutics?
Currently, no hedge funds are holding shares in SEELQ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Seelos Therapeutics
Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It focuses on development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system disorders. Its portfolio include late-stage clinical assets targeting psychiatric and movement disorders. The company is headquartered in New York, NY.
Salarius Pharmaceuticals
―
Scinai Immunotherapeutics
―
Enveric Biosciences
―
GRI Bio
―
Dermata Therapeutics
―
Ownership Overview
―
Insiders
1.04% Mutual Funds
1.83% Other Institutional Investors
97.14% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---